CIK 0001557746
- Non-accelerated filer
- Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460571712
- Phone
- +1 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-10-13 | VIVO VENTURES VII, LLC 10% owner | Conversion · Series C Preferred Stock | −1,346,068 | 0 | ||
| 2015-10-13 | VIVO VENTURES VII, LLC 10% owner | Conversion · Series C Preferred Stock | −29,337 | 0 | ||
| 2015-10-13 | Mehra Anand Director | Conversion | +1,880,390 | 1,880,390 | ||
| 2015-10-13 | Mehra Anand Director | Purchase | +409,090 | $11.00 | $4.5M | 2,289,480 |
| 2015-10-13 | Mehra Anand Director | Conversion · Series A Preferred Stock | −2,000,000 | 0 | ||
| 2015-10-13 | Mehra Anand Director | Conversion · Series B Preferred Stock | −2,424,242 | 0 | ||
| 2015-10-13 | Mehra Anand Director | Conversion · Series C Preferred Stock | −2,063,107 | 0 | ||
| 2015-10-13 | Sofinnova Venture Partners VIII, L.P. 10% owner | Conversion | +1,880,390 | 1,880,390 | ||
| 2015-10-13 | Sofinnova Venture Partners VIII, L.P. 10% owner | Purchase | +409,090 | $11.00 | $4.5M | 2,289,480 |
| 2015-10-13 | Sofinnova Venture Partners VIII, L.P. 10% owner | Conversion · Series A Preferred Stock | −2,000,000 | 0 | ||
| 2015-10-13 | Sofinnova Venture Partners VIII, L.P. 10% owner | Conversion · Series B Preferred Stock | −2,424,242 | 0 | ||
| 2015-10-13 | Sofinnova Venture Partners VIII, L.P. 10% owner | Conversion · Series C Preferred Stock | −2,063,107 | 0 | ||
| 2015-10-13 | Ali-Jackson Kamil Chief Legal Officer | Conversion | +3,738 | 24,027 | ||
| 2015-10-13 | Ali-Jackson Kamil Chief Legal Officer | Conversion · Series A Preferred Stock | −10,000 | 0 | ||
| 2015-10-13 | Ali-Jackson Kamil Chief Legal Officer | Conversion · Series B Preferred Stock | −2,901 | 0 | ||
| 2015-10-13 | Ruffo Frank Chief Financial Officer | Conversion | +7,478 | 137,912 | ||
| 2015-10-13 | Ruffo Frank Chief Financial Officer | Conversion · Series A Preferred Stock | −20,000 | 0 | ||
| 2015-10-13 | Ruffo Frank Chief Financial Officer | Conversion · Series B Preferred Stock | −5,802 | 0 | ||
| 2015-10-13 | Tullman Stephen A. Director | Conversion | +46,188 | 394,014 | ||
| 2015-10-13 | Tullman Stephen A. Director | Conversion · Series A Preferred Stock | −110,000 | 0 |
Page 56 of 57 · 1,130 trades